title: Exacerbations of bipolar disorder triggered by chloroquine in systemic lupus erythematosus--a case report.
abstract: Despite precise definitions and exclusions for 19 syndromes of neuropsychiatric systemic lupus erythematosus (NPSLE), under some circumstances it appears to be difficult to differentiate whether neuropsychiatric symptoms are caused by SLE or by other reasons such as primary mental disorders or substance-induced mood disorders, especially induced by glucocorticoids or antimalarials. We report the case of a male patient with SLE who presented with an exacerbation of bipolar disorder triggered by chloroquine. Firstly, when the patient was diagnosed with SLE, he underwent six months of therapy with chloroquine without any psychiatric symptoms. Later, the SLE returned and the patient was prescribed chloroquine again, without any mental illness. When the third exacerbation of SLE occurred, it coincided with a severe depressive episode with psychotic features that became aggravated for the first time after the administration of chloroquine. The chloroquine was subsequently replaced with hydroxychloroquine for the next six months without any behavioral problems, following which, the SLE and mood disorder were in remission. Later, a bipolar disorder relapse occurred, manifested by a manic episode, and in the following three months, despite psychiatric treatment, a manic episode with psychotic features developed four days after chloroquine was prescribed for arthritis. It was the second time that the mood disorder was exacerbated by chloroquine. Since that time, chloroquine has been withdrawn. Currently the patient is undergoing treatment with hydroxychloroquine and psychiatric drugs with good response. Our case points out that although chloroquine-induced psychosis is rare, patients presenting with behavioral changes need physicians' attention in order to diagnose early and efficiently treat encountered mood disorders.
authors.affiliation: 1Department of Dermatology and Venereology, Medical University of Lodz, Poland.
authors.forename: J
authors.initials: J
authors.lastname: Bogaczewicz
authors.forename: T
authors.initials: T
authors.lastname: Sobów
authors.forename: A
authors.initials: A
authors.lastname: Bogaczewicz
authors.forename: E
authors.initials: E
authors.lastname: Robak
authors.forename: P
authors.initials: P
authors.lastname: Bienkowski
authors.forename: A
authors.initials: A
authors.lastname: Sysa-Jedrzejowska
authors.forename: A
authors.initials: A
authors.lastname: Wozniacka
mesh_terms: D000328:Adult; D000962:Antimalarials / Q000009:adverse effects / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000139:chemically induced / Q000188:drug therapy / Q000209:etiology*; D002738:Chloroquine / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D006886:Hydroxychloroquine / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000150:complications* / Q000188:drug therapy* / Q000523:psychology; D020945:Lupus Vasculitis, Central Nervous System / Q000150:complications / Q000188:drug therapy / Q000523:psychology; D008297:Male
chemical_list: D000962:Antimalarials; D006886:Hydroxychloroquine; D002738:Chloroquine
keywords: Systemic lupus erythematosus; chloroquine; neuropsychiatric lupus